Pharnext announces the consolidation of its shares and the suspension of the right to exercise securities giving access to capital, including conversions of convertible bonds – 10/03/2022 at 6:00 p.m.


• Consolidation by way of exchange of 5,000 existing shares for 1 new share

• Start of the consolidation operation on Monday, October 24, 2022

• Effective date of the merger on Wednesday, November 23, 2022

• Suspension of the right to exercise securities giving access to capital from Friday October 21 (inclusive) to Tuesday November 22, 2022 (inclusive)

PARIS, France, October 3, 2022 at 6:00 p.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today oday that its Board of Directors has decided to implement a consolidation of the shares making up its share capital, at the rate of 1 new share with a nominal value of 1 euro against 5,000 old shares with a nominal value of 0, 0002 euro, as authorized by the General Meeting of June 17, 2022 under the terms of its eighth resolution.



Source link -86